Efficacy of micafungin, a candin antifungal agent, in guinea pig models of disseminated candidiasis and pulmonary aspergillosis
The efficacy of micafungin (MCFG) and voriconazole (VRCZ) was evaluated in guinea pig models of disseminated candidiasis and pulmonary aspergillosis. MCFG and VRCZ were administered twice daily for 9 days starting at 2-4 hour after infection by subcutaneous injection and oral administration, respect...
Saved in:
| Published in | Japanese Journal of Chemotherapy Vol. 54; no. 3; pp. 255 - 259 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
Japanese Society of Chemotherapy
2006
公益社団法人 日本化学療法学会 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1340-7007 1884-5886 |
| DOI | 10.11250/chemotherapy1995.54.255 |
Cover
| Abstract | The efficacy of micafungin (MCFG) and voriconazole (VRCZ) was evaluated in guinea pig models of disseminated candidiasis and pulmonary aspergillosis. MCFG and VRCZ were administered twice daily for 9 days starting at 2-4 hour after infection by subcutaneous injection and oral administration, respectively. MCFG and VRCZ significantly prolonged the survival of guinea pigs infected intravenously with Candida albicans at doses of 0.32 and 1mg/kg, respectively (p<0.05). MCFG and VRCZ significantly prolonged the survival of guinea pigs infected intratracheally with Aspergillus fumigatus at doses of 1.00 and 3.2mg/kg, respectively (p<0.01). These results supported the efficacy of clinical doses of MCFG and VRCZ in treating disseminated candidiasis and pulmonary aspergillosis. |
|---|---|
| AbstractList | The efficacy of micafungin (MCFG) and voriconazole (VRCZ) was evaluated in guinea pig models of disseminated candidiasis and pulmonary aspergillosis. MCFG and VRCZ were administered twice daily for 9 days starting at 2-4 hour after infection by subcutaneous injection and oral administration, respectively. MCFG and VRCZ significantly prolonged the survival of guinea pigs infected intravenously with Candida albicans at doses of 0.32 and 1mg/kg, respectively (p<0.05). MCFG and VRCZ significantly prolonged the survival of guinea pigs infected intratracheally with Aspergillus fumigatus at doses of 1.00 and 3.2mg/kg, respectively (p<0.01). These results supported the efficacy of clinical doses of MCFG and VRCZ in treating disseminated candidiasis and pulmonary aspergillosis. The efficacy of micafungin (MCFG) and voriconazole (VRCZ) was evaluated in guinea pig models of disseminated candidiasis and pulmonary aspergillosis. MCFG and VRCZ were administered twice daily for 9 days starting at 2-4 hour after infection by subcutaneous injection and oral administration, respectively. MCFG and VRCZ significantly prolonged the survival of guinea pigs infected intravenously with Candida albicans at doses of 0.32 and 1mg/kg, respectively (p<0.05). MCFG and VRCZ significantly prolonged the survival of guinea pigs infected intratracheally with Aspergillus fumigatus at doses of 1.00 and 3.2mg/kg, respectively (p<0.01).These results supported the efficacy of clinical doses of MCFG and VRCZ in treating disseminated candidiasis and pulmonary aspergillosis. モルモットを用いて致死性の播種性カンジダ症および肺アスペルギルス症モデルを作製し, micafungin (MCFG) およびvoriconazole (VRCZ) の延命効果を検討した。感染したモルモットにMCFGを1日2回, 9日間皮下投与してvehicle投与群と生存数変化を比較したところ, 播種性カンジダ症: 0.32mg/kg投与群, 肺アスペルギルス症: 1.0mg/kg投与群において有意な延命効果が認められた。また, VRCZも1日2回, 9日間経口投与して生存数変化を無治療群と比較したところ, 播種性カンジダ症: 1.0mg/kg投与群, 肺アスペルギルス症: 3.2mg/kg投与群で有意な延命効果が認められた。モルモットに両薬剤の5mg/kgを皮下または経口投与したときの血漿中CmaxおよびAUCはヒトにMCFGを50～75mg/body (ヒトの体重を50kgとしたとき1.0～1.5mg/kg) またはヒトにVRCZを3.0～4.0mg/kg静脈内投与したときと近似していることから, MCFGおよびVRCZの臨床投与量において播種性カンジダ症および肺アスペルギルス症に対して有効性を示すことが示唆された。 |
| Author | Matsumoto, Satoru Maki, Katsuyuki Wakai, Yoshimi Ikeda, Fumiaki Hatano, Kazuo Nakai, Toru |
| Author_FL | 中井 徹 波多野 和男 牧 克之 池田 文昭 松本 哲 若井 芳美 |
| Author_FL_xml | – sequence: 1 fullname: 池田 文昭 – sequence: 2 fullname: 松本 哲 – sequence: 3 fullname: 若井 芳美 – sequence: 4 fullname: 中井 徹 – sequence: 5 fullname: 波多野 和男 – sequence: 6 fullname: 牧 克之 |
| Author_xml | – sequence: 1 fullname: Nakai, Toru organization: Pharmacological Research Laboratories, Astellas Pharma Inc – sequence: 1 fullname: Hatano, Kazuo organization: Pharmacological Research Laboratories, Astellas Pharma Inc – sequence: 1 fullname: Wakai, Yoshimi organization: Pharmacological Research Laboratories, Astellas Pharma Inc – sequence: 1 fullname: Matsumoto, Satoru organization: Pharmacological Research Laboratories, Astellas Pharma Inc – sequence: 1 fullname: Maki, Katsuyuki organization: Pharmacological Research Laboratories, Astellas Pharma Inc – sequence: 1 fullname: Ikeda, Fumiaki organization: Post Marketing Product Development, Astellas Pharma Inc |
| BackLink | https://cir.nii.ac.jp/crid/1390282681262126592$$DView record in CiNii |
| BookMark | eNpdUD1v3DAMFYoEaJrkP2joGF8lWfJJYxGkaYEDurSzQUmUw8CWDcs33JS_Hh2uQ9CBH3h874HkF3aV54yMcSl2UiojvoUXnObtBVdYTtI5szN6p4z5xG6ktbox1nZXtW-1aPZC7D-z-1LICyGl6FrpbtjbU0oUIJz4nPhUu3TMA-UHDjxAjpQ55I3OIIwcBszbA6_gcKSMwBca-DRHHMtZHqkUnCjDhvGijgSFSrWIfDmO05xhPXEoC64DjeNcZ3fsOsFY8P5fvWV_fzz9efzZHH4__3r8fmhelTJbk_bee-VsMg7ACoHCdxqU1sJ7p60x3u8Rkw0JY-esSp0xbUwqhAgaEdtb9vXim4n6QOcsWyeUVZ2VqlM1jFOVdrjQXstWr-2Xlaa6cw_rRmHE_v9_90b37SXVt3-gwdpjbt8BnrKEog |
| ContentType | Journal Article |
| Copyright | Japanese Society of Chemotherapy |
| Copyright_xml | – notice: Japanese Society of Chemotherapy |
| DBID | RYH |
| DOI | 10.11250/chemotherapy1995.54.255 |
| DatabaseName | CiNii Complete |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | モルモットの播種性カンジダ症および肺アスペルギルス症モデルにおけるｍｉｃａｆｕｎｇｉｎの治療効果 |
| DocumentTitle_FL | モルモットの播種性カンジダ症および肺アスペルギルス症モデルにおけるｍｉｃａｆｕｎｇｉｎの治療効果 |
| EISSN | 1884-5886 |
| EndPage | 259 |
| ExternalDocumentID | 130004298293 article_chemotherapy1995_54_3_54_3_255_article_char_en |
| GroupedDBID | 5GY ALMA_UNASSIGNED_HOLDINGS DIK JSF KQ8 P2P RJT RYH |
| ID | FETCH-LOGICAL-j225t-f7bbb298f59aa800e0b64a2440bb94855bb7eef8cfed6982f6553df2ccda4eee3 |
| ISSN | 1340-7007 |
| IngestDate | Thu Jun 26 21:58:01 EDT 2025 Wed Sep 03 06:25:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j225t-f7bbb298f59aa800e0b64a2440bb94855bb7eef8cfed6982f6553df2ccda4eee3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/chemotherapy1995/54/3/54_3_255/_article/-char/en |
| PageCount | 5 |
| ParticipantIDs | nii_cinii_1390282681262126592 jstage_primary_article_chemotherapy1995_54_3_54_3_255_article_char_en |
| PublicationCentury | 2000 |
| PublicationDate | 2006 |
| PublicationDateYYYYMMDD | 2006-01-01 |
| PublicationDate_xml | – year: 2006 text: 2006 |
| PublicationDecade | 2000 |
| PublicationTitle | Japanese Journal of Chemotherapy |
| PublicationTitleAlternate | Jpn. J. Chemother. |
| PublicationTitle_FL | Jpn. J. Chemother 日化療会誌 日本化学療法学会雑誌 |
| PublicationYear | 2006 |
| Publisher | Japanese Society of Chemotherapy 公益社団法人 日本化学療法学会 |
| Publisher_xml | – name: Japanese Society of Chemotherapy – name: 公益社団法人 日本化学療法学会 |
| References | 18) Hatano K, Morishita Y, Nakai T, et al: Antifungal mechanism of FK463against Candida albicans and Aspergillus fumigatus.J Antibiot 55: 219-222, 2002 8) Chandrasekar P H, Cutright J, Manavathu E: Efficacy of voriconazole against invasive pulmonary aspergillosis inguinea-pig model. J Antimicrob Chemother 45: 673-676, 2000 6) George D. Minter P, Andoriole V T: Efficacy of UK-109496, a new azole antifungal agents, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 40: 86-91, 1996 10) Perea S. Pennick G J, Modak A, et al: Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother 44: 1209-1213, 2000 14) Andes D, Marchillo K, Stamstad T, et al: In vivo pharamacokinetics and pharmacodynamics of a new triazole, voriconazole, in murine candidiasis model. Antimicrob Agents Chemother 47: 3165-3169, 2003 3) 松本哲, 若井芳美, 渡部悦子, 他: Candida属及びAspergillus fumigatusによるマウス全身感染に対するmicafunginの防御効果. 日化療会誌50 (Suppl 1): 30-36, 2002 7) Kirkpatrick W R, Mcatee R K, Fothergill A W, et al: Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 44: 2865-2868, 2000 5) Roffey S J, Cole S, Comby P. et al: The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog and human. Drug Metab Dispos 31: 731-741, 2003 17) Purkins L, Wood N, Greenhalgh K, et al: The pharmacokinetics and safety of intravenous voriconazole-a novel wide-spectum antifungal agent, Br J Clin Pharmacol56: s2-9, 2003 9) 山戸康弘, 金子勇人, 谷本薫, 他: ヒト血漿中micafungin およびその代謝物濃度の高速液体クロマト グラフィーによる定量法. 日化療会誌50 (Suppl 1): 68-79, 2002 4) 松本哲, 若井芳美, 渡部悦子, 他; Aspergillus fumigatus によるマウス呼吸器感染に対するmicafunginの防御効果. 日化療会誌50 (Suppl 1): 37-42, 2002 11) National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. NCCLS, Wayne, Pa, 2002 12) National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. NCCLS, Wayne, Pa, 2002 15) Wiederhold N P, Kontoyiannis D P, Chi J, et al: Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190: 1464-1471, 2004 2) Matsumoto S. Wakai Y, Nakai T, et al: Efficacy of FK 463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 44: 619-621, 2000 13) Andes D: In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 47: 1179-1186, 2003 19) Kirkpatrick W R, Perea S, Coco B J, et al: Efficacy of caspofungin alone and in combination with voriconazole in guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother46: 2564-2568, 2002 1) Ikeda F, Wakai Y, Matsumoto S. et al: Efficacy of FK 463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 44: 614-618, 2000 20) Marr K A, Boeckh M, Carter R A, et al: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39: 797-802, 2004 16) 東純一. 中原邦夫, 加賀山彰. 他: Micafunginの高用量での薬物動態試験. 日化療会誌55 (Suppl 1): 155-184, 2002 |
| References_xml | – reference: 12) National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. NCCLS, Wayne, Pa, 2002 – reference: 6) George D. Minter P, Andoriole V T: Efficacy of UK-109496, a new azole antifungal agents, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 40: 86-91, 1996 – reference: 1) Ikeda F, Wakai Y, Matsumoto S. et al: Efficacy of FK 463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 44: 614-618, 2000 – reference: 4) 松本哲, 若井芳美, 渡部悦子, 他; Aspergillus fumigatus によるマウス呼吸器感染に対するmicafunginの防御効果. 日化療会誌50 (Suppl 1): 37-42, 2002 – reference: 5) Roffey S J, Cole S, Comby P. et al: The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog and human. Drug Metab Dispos 31: 731-741, 2003 – reference: 11) National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. NCCLS, Wayne, Pa, 2002 – reference: 17) Purkins L, Wood N, Greenhalgh K, et al: The pharmacokinetics and safety of intravenous voriconazole-a novel wide-spectum antifungal agent, Br J Clin Pharmacol56: s2-9, 2003 – reference: 3) 松本哲, 若井芳美, 渡部悦子, 他: Candida属及びAspergillus fumigatusによるマウス全身感染に対するmicafunginの防御効果. 日化療会誌50 (Suppl 1): 30-36, 2002 – reference: 14) Andes D, Marchillo K, Stamstad T, et al: In vivo pharamacokinetics and pharmacodynamics of a new triazole, voriconazole, in murine candidiasis model. Antimicrob Agents Chemother 47: 3165-3169, 2003 – reference: 15) Wiederhold N P, Kontoyiannis D P, Chi J, et al: Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190: 1464-1471, 2004 – reference: 9) 山戸康弘, 金子勇人, 谷本薫, 他: ヒト血漿中micafungin およびその代謝物濃度の高速液体クロマト グラフィーによる定量法. 日化療会誌50 (Suppl 1): 68-79, 2002 – reference: 10) Perea S. Pennick G J, Modak A, et al: Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother 44: 1209-1213, 2000 – reference: 16) 東純一. 中原邦夫, 加賀山彰. 他: Micafunginの高用量での薬物動態試験. 日化療会誌55 (Suppl 1): 155-184, 2002 – reference: 8) Chandrasekar P H, Cutright J, Manavathu E: Efficacy of voriconazole against invasive pulmonary aspergillosis inguinea-pig model. J Antimicrob Chemother 45: 673-676, 2000 – reference: 7) Kirkpatrick W R, Mcatee R K, Fothergill A W, et al: Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 44: 2865-2868, 2000 – reference: 18) Hatano K, Morishita Y, Nakai T, et al: Antifungal mechanism of FK463against Candida albicans and Aspergillus fumigatus.J Antibiot 55: 219-222, 2002 – reference: 2) Matsumoto S. Wakai Y, Nakai T, et al: Efficacy of FK 463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 44: 619-621, 2000 – reference: 19) Kirkpatrick W R, Perea S, Coco B J, et al: Efficacy of caspofungin alone and in combination with voriconazole in guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother46: 2564-2568, 2002 – reference: 20) Marr K A, Boeckh M, Carter R A, et al: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39: 797-802, 2004 – reference: 13) Andes D: In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 47: 1179-1186, 2003 |
| SSID | ssib001106319 ssib050995465 ssib000940262 ssib001168255 ssib038076210 ssib002822060 ssib002670600 ssib058493824 ssj0003212010 |
| Score | 1.7040706 |
| Snippet | The efficacy of micafungin (MCFG) and voriconazole (VRCZ) was evaluated in guinea pig models of disseminated candidiasis and pulmonary aspergillosis. MCFG and... |
| SourceID | nii jstage |
| SourceType | Publisher |
| StartPage | 255 |
| SubjectTerms | animal model Aspergillus fumigatus Candida albicans micafungin voriconazole |
| Title | Efficacy of micafungin, a candin antifungal agent, in guinea pig models of disseminated candidiasis and pulmonary aspergillosis |
| URI | https://www.jstage.jst.go.jp/article/chemotherapy1995/54/3/54_3_255/_article/-char/en https://cir.nii.ac.jp/crid/1390282681262126592 |
| Volume | 54 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Japanese Journal of Chemotherapy, 2006/05/10, Vol.54(3), pp.255-259 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1884-5886 dateEnd: 20081231 omitProxy: true ssIdentifier: ssj0003212010 issn: 1340-7007 databaseCode: KQ8 dateStart: 19950101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1884-5886 dateEnd: 20081231 omitProxy: true ssIdentifier: ssj0003212010 issn: 1340-7007 databaseCode: DIK dateStart: 19950101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWmZcMGgQBRoMgLdtMMaeykniVCU7UgumEqlVVkJ86Q6XSm6kw2bPpb_TzOjfPwQBGPjZU4DyW-R77H19fHjL01wppwnB0GOixEIHUeBsqKPJByrPMsUoWqZ3Q_nyUn5_LjRXwxGNx5WUvVxoyy7_euK_kfq6IOdqVVsv9g2e6lqMAx7IsSFkb5VzaekP4D7ddOk-Q4gpOaOU0ATdlccEtDTclAqCZJAFpFRRdRPavALvXwupy5vXDqhI56bp5SY4iF1s8DPCRYUosJVAv8F-XYaRIXn5WLxWpdrrfILRwvbWg59FguCRI0i7y64P3ppc318Li6KkFf-5D4Bk23AhX-QnGAqo_0X-py-HW1_lZedTef1ZXT9rYuatH7kvZT2qzU-z7F9cWCkh1DtynuyLo6pWQQq0Y9u-nAnQp1A1Th98ZOAbhx7JGTHv_VZ4AFwtKZ9xG0bn1EIbf2BVuK3DQDSH5cgSrtsAcRRYKIjp9-8ogrxuWeECNIViJ84bzDBENzj6gmpGLkETHwtrAfuNKuAEnUEzWwvDHtYt-dKzkWqlnnQxxEgJGEToqjbcU2jQ1_--43_woWNseYhMQmdpZl6RGt6WP2qMEOf-_g_oQN5vopu22hzlcF76F-wDV3QOc90HkN9AOOSgdzDphzB3N63Ic592COV-S8gznfgvkzdn48mX44CZq9Q4I5PNQmKI6MMTBREY-1xqDIhiaRGlw2NKYWRDLmyNpCZYXNE1iySOJY5EWUZbmW1lrxnO0uV0v7gnGbx5lEC-ooyWVoI50ZK2OyWKQLZdQem7hWS6-dQEzadAjpz82cxjIVrkBre7fpG3Rne2wfjZ5mJZUYmBEISB0Qho8o-eHlH66_Yg_7-OBrtru5qew-GPPGvKnB-QOQWbyp |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+micafungin%2C+a+candin+antifungal+agent%2C+in+guinea+pig+models+of+disseminated+candidiasis+and+pulmonary+aspergillosis&rft.jtitle=Japanese+Journal+of+Chemotherapy&rft.au=Ikeda+Fumiaki&rft.au=Matsumoto+Satoru&rft.au=Wakai+Yoshimi&rft.au=Nakai+Toru&rft.date=2006&rft.pub=Japanese+Society+of+Chemotherapy&rft.issn=1340-7007&rft.eissn=1884-5886&rft.volume=54&rft.issue=3&rft.spage=255&rft.epage=259&rft_id=info:doi/10.11250%2Fchemotherapy1995.54.255&rft.externalDocID=130004298293 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1340-7007&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1340-7007&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1340-7007&client=summon |